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The Hippo pathway regulates the size of organs by controlling
two opposing processes: proliferation and apoptosis. YAP2 (Yes
kinase-associated protein 2), one of the three isoforms of YAP, is
a WW domain-containing transcriptional co-activator that acts as
the effector of the Hippo pathway in mammalian cells. In addition
to WW domains, YAP2 has a PDZ-binding motif at its C-terminus.
We reported previously that this motif was necessary for YAP2
localization in the nucleus and for promoting cell detachment and
apoptosis. In the present study, we show that the tight junction
protein ZO (zonula occludens)-2 uses its first PDZ domain to form
a complex with YAP2. The endogenous ZO-2 and YAP2 proteins
co-localize in the nucleus. We also found that ZO-2 facilitates
the nuclear localization and pro-apoptotic function of YAP2, and
that this activity of ZO-2 is PDZ-domain-dependent. The present
paper is the first report on a PDZ-based nuclear translocation
mechanism. Moreover, since the Hippo pathway acts as a tumour
suppressor pathway, the YAP2–ZO-2 complex could represent a
target for cancer therapy.
Key words: Hippo pathway, nuclear translocation, PDZ domain,
Yes kinase-associated protein 2 (YAP2), zona occludens protein.
INTRODUCTION
YAP (Yes kinase-associated protein) is one of the effectors of
the Hippo pathway that controls the size of organs by co-
ordinating two opposing processes: proliferation and cell death
[1]. Originally, the YAP gene was isolated by functional cloning,
as Yes- and Src-kinase-binding protein [2]. Subsequently, YAP
was shown to act as a transcriptional co-activator downstream
of various signalling complexes [3–6]. However, the most
compelling evidence for YAP function came from genetic
analyses in Drosophila, which revealed an oncogene-like activity
of YAP and its fly orthologue, Yki (Yorkie) [7].
There are three major isoforms of YAP, named YAP1, YAP2
and YAP2-L (YAP2-long), which are generated by differential
splicing [4,8]. YAP1 contains one WW domain, YAP2 contains
two WW domains and YAP2-L has a 16-amino-acid-long insert
within its transcriptional activation domain [4]. WW domains
are small protein modules known to mediate protein complexes
by interaction with linear proline-rich peptide motifs in cognate
proteins [9,10]. Apart from WW domains, YAP also contains a
transcriptional activation domain and a C-terminally located PDZ-
domain-binding motif. YAP has the ability to translocate from the
cytoplasm to the nucleus, a process controlled by phosphorylation
and also by WW- and PDZ-domain-mediated complexes with
several cytoplasmic proteins [11–14].
We reported previously that when human embryonic HEK
(human embryonic kidney)-293 cells were grown in medium
containing 1% serum, YAP2, but not YAP1, was able to stabilize
the pro-apoptotic protein p73 and thus promote cell apoptosis
[13]. We also confirmed that the cytoplasmic localization of
YAP2 was dependent on YAP2 phosphorylation at Ser127 by the
kinase Lats1 (large tumour suppressor 1). We further showed that
the PDZ-binding motif was required for promoting apoptosis in
cells grown in low serum [14]. In addition, our results showed
that the PDZ-binding motif was necessary for YAP2 localization
in the nucleus, as a YAP2 mutant with a deleted PDZ-binding
motif was found only in the cytoplasm. In summary, these recent
results pointed to the existence of an unknown PDZ-domain-
containing protein (or proteins), which could act as a shuttle,
facilitating YAP2 translocation from the cytoplasm to the nucleus.
In the present study we show that ZO (zona occludens)-2, which
associates with tight junctions, is one of the candidate proteins
that control the localization of YAP2.
Among the prominent components of the tight junction-
associated proteins are the ZO proteins ZO-1, -2 and -3. They
belong to the MAGUK (membrane-associated guanylate kinase)
protein family. Like other MAGUKs, the ZO proteins contain
three N-terminally located PDZ domains, one SH3 (Src homology
3) domain, a GUK (guanylate kinase) homology domain and a
proline-rich C-terminal region. All three proteins show extensive
Abbreviations used: CSDA, cold-shock domain protein A; DMEM, Dulbecco’s modified Eagle medium; EMT, epithelial-to-mesenchymal transition; FBS,
fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; GST, glutathione transferase; GUK, guanylate
kinase; HEK, human embryonic kidney; INADL, inactivation no afterpotential D-like; ITC, isothermal titration calorimetry; Lats1, large tumour suppressor
1; MAGUK, membrane-associated GUK; MDCK, Madin–Darby canine kidney; MPDZ, multiple PDZ domain protein; NLS, nuclear localization signal; NES,
nuclear export signal; PARP, poly(ADP-ribose) polymerase; RNAi, RNA interference; RUNX2, runt-related transcription factor 2; SH3, Src homology 3; TAZ,
transcriptional co-activator with PDZ-binding motif; WT, wild-type; WWTR1, WW-domain-containing transcription regulator 1; YAP, Yes kinase-associated
protein; Yki, Yorkie; ZO, zona occludens.
1 E. R., K. M., B. V., C. B., J. G. and M. S. dedicate this paper to Professor J. Vandekerckhove on the occasion of his retirement, with appreciation of his
many important contributions to molecular and cellular biology.
2 To whom correspondence should be addressed (email msudol1@geisinger.edu).
c© The Authors Journal compilation c© 2010 Biochemical Society
www.biochemj.org
B
io
ch
em
ic
al
 J
ou
rn
al
462 T. Oka and others
sequence similarity to each other, especially within their equival-
ent PDZ domains [15]. Both ZO-2 and -3 can heterodimerize
with ZO-1 through their second PDZ domain, but not with
each other [16–19]. At tight junctions, ZO-1, -2, and -3 bind
to claudins, JAM (junction adhesion molecule) and occludin [20–
22]. They also bind actin filaments [19,23,24] and other signalling
proteins, serving as putative adaptors in the assembly of signalling
complexes [25]. However, the exact function of ZO proteins in
the formation and maintenance of tight junctions is still unknown.
The subcellular distribution of ZO proteins seems to be sensitive
to the degree of cell–cell contact [26,27]. Generally, ZO-1 and -2
concentrate in the nuclei of sparsely populated epithelial cells,
whereas in confluent monolayers they tend to accumulate at
tight junctions. This suggests that ZO proteins could transmit
information about the state of cell–cell contact to the nucleus,
and such signals could maintain balance between proliferation
and differentiation. Both ZO-1 and ZO-2 proteins contain NLSs
(nuclear localization signals) and NESs (nuclear export signals),
but the function of these signals was verified only for ZO-
2 [28,29]. Nuclear ZO-2 regulates gene expression through
its association with various transcription factors including Jun,
Fos and C/EBP (CCAAT/enhancer-binding protein) [30]. ZO-1
has also been shown to regulate gene expression through the
transcription factor CSDA (cold-shock domain protein A; also
known as ZONAB and DbpA). CSDA stimulates cell proliferation
in epithelial cells, and this process is negatively regulated by ZO-1,
which sequesters the transcription factor at tight junctions [31,32].
The previous reports showing the involvement of YAP2 in the
regulation of cell adhesion [13] and in cell-density-dependent
nuclear localization of YAP [33] prompted us to study the function
of the potential complex between YAP2 and ZO-2 proteins.
We show in the present study that: (i) the complex between
endogenous YAP2 and ZO-2 proteins could be visualized by
immunostaining and co-immunoprecipitation; (ii) the PDZ-
binding motif in YAP2 and the first PDZ domain in ZO-2 are
required for the formation of the complex; (iii) the overexpression
of ZO-2 affected the subcellular localization of YAP2; and (iv)
that ZO-2 co-operated with YAP2 to enhance detachment of HEK-
293 cells, but to inhibit YAP2-induced proliferation of MDCK
(Madin–Darby canine kidney) cells. The novelty of the present
work is in implicating the PDZ domain and the PDZ domain-
containing protein ZO-2 in the mechanism of nuclear transport.
EXPERIMENTAL
Cell culture and transfections
HEK-293 and MDCK cells were from the A.T.C.C. and cultured
in DMEM (Dulbecco’s modified Eagle medium) with 10%
(v/v) FBS (fetal bovine serum). MCF7 cells were cultured in
Eagle’s minimum essential medium containing 10% (v/v) FBS
and 10 μg/ml insulin (Sigma–Aldrich). MCF10A cells were
cultured in MEGM (mammary epithelial cell growth medium)
containing 10% (v/v) FBS, 50 μg/ml BPE (bovine pituitary
extract), 0.5 μg/ml hydrocortisone (Sigma–Aldrich), 10 μg/ml
insulin, 20 ng/ml EGF (epidermal growth factor; Sigma–Aldrich)
and 0.1 μg/ml cholera toxin (Calbiochem). HEK-293 cells were
transfected using LipofectamineTM (Invitrogen), according to
the manufacturer’s instructions, and GenJetTM in vitro DNA
transfection reagent (SignaGen) was used to transfect plasmids
into MDCK cells.
Antibodies and immunoprecipitation
Anti-Flag-M2 antibody and anti-ZO-2 antibody were from
Sigma–Aldrich and Santa Cruz Biotechnology respectively.
Antibodies against ZO-1 and ZO-2 for immunostaining were
from Invitrogen. Anti-GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) antibody was from Abcam and anti-PARP
[poly(ADP-ribose) polymerase] antibody was from Roche
Applied Science. The polyclonal anti-YAP antibody was gener-
ated in rabbits as described previously [8]. Immunoprecipitation
was conducted as described previously [13,14]. To purify
overexpressed Flag–YAP2 from HEK-293 cell lysates, 3 × Flag
peptide (Sigma) was used according to the manufacture’s instru-
ctions.
Immunostaining
Cultured cells were grown on glass coverslips, washed with PBS
and fixed in 3% (w/v) paraformaldehyde. After permeabilization
with 0.1% Triton X-100 in PBS, cells were blocked in 1% (w/v)
BSA in PBS and incubated with primary antibody at 37 ◦C for
1 h or at 4 ◦C overnight, followed by Alexa Fluor® 594 goat anti-
rabbit (for YAP) or Alexa Fluor® 488 anti-mouse (for ZO proteins)
IgG (Molecular Probes) for 30 min at room temperature (25 ◦C).
Stained cells were examined using an Apotome Zeiss Axioplan II
epifluorescence microscope. Images were captured using a cooled
CCD (charge-coupled-device) Axiocam Camera and Axiovision
4.4 software (Zeiss).
Plasmids
Human ZO-2 cDNA in pOTB7 vector was purchased from
Open Biosystems. The amplified PCR product was subcloned
into pBluescript vector (Stratagene) by utilizing KpnI and XbaI
sites that had been incorporated into the primers. This insert
was subcloned into pEGFP-C3 vector (Clontech), p2 × Flag-
CMV2 vector and pcDNA4/TO/myc-His vector (Invitrogen)
using the KpnI and XbaI sites. ZO-2-N, a truncated fragment
of ZO-2-WT (wild-type), was subcloned from pBluescript-ZO-
2-WT into pEGFP-C3 vector, p2 × Flag-CMV2 vector, and
pcDNA4/TO/myc-His vector using the KpnI and BamHI/BglII
sites. ZO-2-PDZm has four point mutations in its first PDZ domain
(K38E, F44H, I46E and V48E). The ZO-2 gene containing these
mutations was synthesized by Epoch Biolabs and the mutated
fragment was exchanged with ZO-2-WT in p2 × Flag-CMV2
vector using the KpnI and BglII sites. The resulting plasmid
was subcloned into the pEGFP-C3 and pcDNA4/TO/myc-His
vectors using the KpnI and XbaI sites. ZO-2-NLS lacks two
putative NLSs, and this ZO-2-deleted fragment (313–873 bp) was
synthesized by Epoch Biolabs prior to subcloning into p2 × Flag-
CMV2 vector. ZO-2-N, lacking 1–351 bp, has its first PDZ
domain completely deleted. Its PCR fragment was subcloned into
p2 × Flag-CMV2 vector using KpnI and XbaI sites embedded
into the primers. ZO-2-NLS and ZO-2-N expression plasmids
were constructed as for ZO-2-PDZm. YAP2-WT and several
Flag–ZO-2 cDNAs in p2 × Flag-CMV2 vector were subcloned
into pBABE-puro vector or pBABE-hygro vector (Addgene).
HA (haemagglutinin)–YAP2–5SA was a gift from Dr Xiaolong
Yang (Queen’s University, Ontario, Canada) and its cDNA was
subcloned into pBABE-puro vector.
ZO-2-WT and ZO-2-NLS in p2 × Flag-CMV2 vector
(Sigma–Aldrich) were used as templates for PCR to construct
GST (glutathione transferase)-fused human ZO-2. PCR was per-
formed to amplify the cDNA of human ZO-2 using two pri-
mer sets: 5′-AGAGGATCCATGCCGGTGCGAGGAGACC-
GC-3′ and 5′-AGACTCGAGCGGCCGCCCCCTAGGCTCG-
GG-3′, and 5′-AGAGGATCCGAAGATGAAGCAATATATGG-3′
and 5′-AGACTCGAGAGCCAGGATGTCTCTATACAC-3′. The
c© The Authors Journal compilation c© 2010 Biochemical Society
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amplified fragments were inserted into pGEX4T3 vector to
generate GST–human-ZO-2–1stPDZ-WT and GST-human-ZO-
2–2ndPDZ-NLS respectively.
Mouse ZO-2 cDNA was a gift from Dr S. Tsukita (Osaka
University, Suita, Japan). Each of its three individual PDZ
domains were cloned into the pGEX2TK vector using the
BamHI and EcoRI sites (Amersham Pharmacia Biotech) and
were named GST–1stPDZ, GST–2ndPDZ and GST–3rdPDZ
respectively. The recombinant plasmids generated in the present
study have been deposited in the Addgene plasmid repository
(http://www.addgene.org). All other plasmids were as described
previously [13,14].
Human ZO-1 cDNA in the pCR-Blunt II-TOPO vector was
purchased from Open Biosystems. The amplified PCR product
was subcloned into p2 × Flag-CMV2 vector in the same manner
as for ZO-2.
GST-tagged protein expression and binding assay
The expression of GST-tagged proteins was induced by adding
IPTG (isopropyl β-D-thiogalactopyranoside). The cells were
harvested prior to adding Triton buffer [50 mM Tris/HCl, pH 7.45,
150 mM NaCl, 1 mM EDTA and 1% (v/v) Triton X-100]. Cell
debris was removed by centrifugation (16100 g for 10 min), and
glutathione–Sepharose 4B (Amersham Biosciences) was added
to the supernatant and incubated for 1 h. The resin was washed
with Triton buffer and then purified Flag–YAP2-WT from HEK-
293 cell lysates was incubated with the resin for 2 h. The
resin was washed again with Triton buffer and bound proteins
were separated by SDS/PAGE followed by immunoblotting or
Coomassie Blue staining.
RNAi (RNA interference) treatment and cell counting assay
The RNAi oligonucleotide against ZO-2 and the control oligonuc-
leotide were purchased from Santa Cruz Biotechnology and Euro-
gentec. siRNA duplexes targeting canine ZO-2 were as follows:
sense sequence, 5′-GCAGCAGUAUUCCGACUAUdTdT-3′ and
antisense sequence, 5′-AUAGUCGGAAUACUGCUGCdTdT-3′.
MDCK cells were transfected with 50 nM siRNA duplexes
using Lipofectamine 2000TM (Invitrogen) according to the
manufacturer’s instructions. A negative control siRNA duplex,
obtained from Eurogentec, was used under similar conditions.
HEK-293 cells that express YAP2-WT in an inducible system
[13,14] were plated at approx. 5% confluency in DMEM,
1% (v/v) FBS and 5 μg/ml blasticidin. Expression of YAP2
was induced by 1 μg/ml tetracycline. Transfections of the
RNAi oligonucleotides were conducted using LipofectamineTM.
After 96 h, floating cells were removed and attached cells were
trypsinized and counted. For the cell counting assay without
RNAi treatment, HEK-293 cells were transfected with Flag-
tagged plasmids. After 24 h, the cells were distributed into new
plates and maintained in DMEM with 1% (v/v) FBS for 96 h.
After the removal of floating cells, attached cells were counted as
described above. MDCK cells were maintained in DMEM with
0.5% FBS for 96 h. The expression of proteins was checked by
Western blotting.
Establishment of MDCK and MCF10A cells that stably express YAP2
and ZO-2
MDCK cells were transfected with pBABE-puro-YAP2-WT,
pBABE-puro-Flag-ZO-2 (-WT or -NLS) or pBABE-puro
control vector. Cells which failed to express these plasmids
were removed by adding puromycin (Sigma–Aldrich) to a
final concentration of 2 μg/ml. After the selection, cells were
transfected with either pBABE-hygro or pBABE-hygro vectors
containing ZO-2s. Selection was performed again by adding both
2 μg/ml puromycin and 400 μg/ml hygromycin (Invitrogen).
Single cell isolation was never performed when cells were
selected. The same procedure was performed for MCF10A
cells except lower concentrations of puromycin (0.5 μg/ml) and
hygromycin (200 μg/ml) were used, and pBABE-puro-YAP2–
5SA was used instead of pBABE-puro-YAP2-WT.
RESULTS
Endogenous ZO-2 co-localizes with endogenous YAP in several cell
lines
The C-terminal sequence of YAP (FLTWL) represents a well-
conserved motif that binds to one of the 16 subclasses of
PDZ domains [34,35]. By scanning billions of random peptides
with 82 PDZ domains from human and Caenorhabditis elegans
proteomes, a map of binding specificities was completed [35].
We used this map to predict several PDZ domains and their
host proteins as putative partners of YAP. Four PDZ domain-
containing proteins displayed a specificity profile that matched
the C-terminus of YAP: the ZO family, MPDZ (multiple
PDZ domain protein), SLC9A3R2 [solute carrier family 9
(sodium/hydrogen exchanger), member 3 regulator 2] and INADL
(inactivation no afterpotential D-like) (Supplementary Figure S1
at http://www.BiochemJ.org/bj/432/bj4320461add.htm). To test
these predictions we used commercial polyclonal antibodies
against human ZO-2, MPDZ and INADL and documented that
YAP could be co-precipitated from HEK-293 cells only with
anti-ZO-2 antibody (results not shown). Therefore we focused
our efforts on the ZO–YAP complex. The FLTWL C-terminal
sequence of YAP matches the consensus sequence of peptides
that bind to the first PDZ domain of the ZO family of proteins
[36]. The sequence similarity among the first PDZ domains of
ZO family members ZO-1, ZO-2 and ZO-3 is high (between
ZO-1 and ZO-2 domains identities are 70%; between ZO-1
and ZO-3 identities are 55%). Therefore one could predict
that each of the three ZO proteins would bind to YAP through
their first PDZ domain. ZO proteins are integral components of
tight junctions [37]. However, several reports have shown that
ZO-2 has a propensity to localize to the nucleus [28,29,38],
and that ZO-2 has putative NLSs (Supplementary Figure S2
at http://www.BiochemJ.org/bj/432/bj4320461add.htm). ZO-1 is
usually present in tight junctions, but under some conditions, it has
also been observed in the cell nucleus [26]. ZO-3 is the least well-
characterized member of the ZO family in terms of the potential
ability to shuttle between the cytoplasm and the nucleus, therefore
we decided not to include it in the present study.
To determine whether YAP and ZO proteins co-localize in
cells, we immunostained MDCK cells for endogenous ZO-1, ZO-
2 and YAP proteins (Figure 1A). YAP gave a strong signal in
the nucleus, whereas the majority of the ZO-1 signal was in the
membrane. YAP and ZO-1 barely co-localized in MDCK cells. In
contrast, ZO-2 immunoreactivity was concentrated in the nucleus
and its distribution in MDCK cells was almost identical with
that of YAP (Figure 1A). These results suggest that in contrast
with ZO-1, ZO-2 may form a functional complex with YAP in
MDCK cells. In MCF10A cells and MCF7 cells, ZO-2 and YAP
also co-localized in the nucleus (Figure 1B). Knowing that ZO-1
and ZO-2 could heterodimerize via their second PDZ domains,
we investigated whether YAP2, ZO-1 and ZO-2 could form a
tripartite complex. Both YAP2 and ZO-2 were co-precipitated
with ZO-1, suggesting that these three proteins could form a
tripartite complex in vivo (Figure 1C). Judging from the ratio of
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Figure 1 Endogenous ZO-2 co-localizes with endogenous YAP in MDCK cells
(A) Endogenous ZO-1, ZO-2 and YAP2 in MDCK cells were immunostained and observed with a microscope. Scale bar, 20 μm. (B) Endogenous ZO-2 and YAP2 in indicated cell lines were
immunostained and observed with a microscope. Scale bar, 20 μm. (C) ZO-1, ZO-2 and YAP2 form a complex. Flag–ZO-1-WT, Myc–His–ZO-2-WT and Myc–His–YAP2-WT were co-transfected
into HEK-293 cells. Cell lysates were immunoprecipitated (IP) with either control IgG or an anti-Flag antibody, resolved on SDS gels and immunoblotted (IB) with the indicated antibodies. Molecular
masses (MW) are indicated in kDa on the left-hand side. (D) Endogenous ZO-2 binds to endogenous YAP in MDCK cells. MDCK cells were maintained in two different conditions. One was very
sparsely distributed and the other was very dense (overgrowth). To keep the cells healthy, the medium was exchanged every 24 h for 5 days after the cells had reached confluency. The same amount
of MDCK cell lysates were used for immunoprecipitation. The cell lysates were immunoprecipitated with either control IgG or an anti-YAP antibody, resolved on SDS gels and immunoblotted with
anti-ZO-2 or anti-YAP antibodies. Molecular masses are indicated in kDa on the left-hand side. (E) Endogenous ZO-2 binds to endogenous YAP in both cytosol and nucleus of MDCK cells. Cytosolic
and nuclear fractions of MDCK cells were separated by using CelLyticTM NuCLEARTM extraction kit (Sigma–Aldrich). These fractions were immunoprecipitated with either control IgG or anti-YAP
antibody, resolved on SDS gels and immunoblotted with indicated antibodies. Molecular masses are indicated in kDa on the left-hand side. (F) Both YAP and ZO-2 were slightly increased in the
nucleus when MDCK cells were sparsely distributed. MDCK cells were maintained as described in (D), and cytosolic and nuclear fractions were separated as described in (E). A total of 50 μg of
extracts was run on each lane, followed by immunoblotting with indicated antibodies to monitor the distribution of endogenous proteins. Molecular masses are indicated in kDa on the left-hand side.
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signal between the input and the immunoprecipitated fraction,
ZO-1 binds to ZO-2 more tightly than to YAP2. To test whether
the association of YAP and ZO-2 changes depending on the
state of cell confluency, MDCK cells were maintained in sparse
or dense conditions; however, consistently, we did not detect
significant changes in the YAP2–ZO-2 complex as a function
of cell density (Figure 1D). The association of endogenous ZO-
2 and YAP in the nucleus and cytosol was confirmed when
immunoprecipitation was conducted using nuclear and cytosol
fractions of MDCK cells (Figure 1E). It was shown previously that
ZO-2 accumulated in the nucleus when MDCK cells were sparsely
distributed, whereas when the cells were densely distributed ZO-
2 could be also found in the cytoplasm [27]. To investigate
whether localization of ZO-2 is accompanied by that of YAP
in MDCK cells, nuclear and cytosol fractions of MDCK cells
were isolated and the distribution of endogenous ZO-2 and YAP
was monitored. However, we observed a less robust change
compared with the results reported previously [27]. Nevertheless,
we re-confirmed that the ratio of ZO-2 in the nucleus compared
with the cytoplasm increased when MDCK cells were sparsely
distributed. As observed for ZO-2, a similar change in the
subcellular distribution was observed for YAP2 (Figure 1F). The
amounts of ZO-2 and YAP in the nucleus slightly decreased
when MDCK cells were densely populated (Figure 1F). On the
basis of these observations, we decided to investigate further
the role of the ZO-2–YAP association in mammalian cells.
YAP2 PDZ-binding motif binds the first PDZ domain of ZO-2
Because ZO-2 has three PDZ domains and YAP2 has a
PDZ-binding motif at its C-terminus, we hypothesized that
ZO-2 associates with YAP2 via its PDZ domain(s). From
the comprehensive map of PDZ-binding specificities [35] we
predicted that only the first PDZ domain of ZO-2 would bind
YAP2. The first, second and third PDZ domains of mouse ZO-2
were individually expressed as GST-fused domains and used
to pull down Flag–YAP2 from HEK-293 cells (Figure 2A). As
expected, only the first PDZ domain of ZO-2 pulled down YAP2.
Using ITC (isothermal titration calorimetry) we determined that
the dissociation constant Kd for the 11-mer peptide of YAP
(KLDKESFLTWL) and the GST–PDZ1 of ZO-2 was 2.3 μM.
A control peptide with a deletion of the last three amino acids
(-TWL) did not result in thermodynamic changes in the ITC
assay (results not shown). Therefore we concluded that the
truncated peptide probably did not interact with the PDZ domain.
Interestingly, the PDZ1 domain of ZO-1 interacted with the YAP
peptide with similar strength (Kd = 3.7 μM) (Figure 2B).
To study the function of the ZO-2–YAP2 complex in detail,
several ZO-2 mutants were constructed. Both ZO-1 and ZO-2
were shown previously to form a complex with ARVCF
(armadillo-repeat gene deleted in velocardiofacial syndrome)
protein, and their PDZ domains were responsible for the asso-
ciation [39]. In that report, four point mutations within the
binding pocket of the first PDZ domain of ZO-1 were shown
to be required to abolish the binding. The equivalents of the
ZO-1 PDZ domain mutations were introduced into the ZO-2
PDZ1 domain (K38E, F44H, I46E and V48E) (see construct
ZO-2-PDZm in Figure 3A and Supplementary Figure S3 at
http://www.BiochemJ.org/bj/432/bj4320461add.htm). Since we
showed that the first PDZ domain bound YAP2, a ZO-2-N
mutant that lacks the first PDZ domain was constructed. We
also generated a mutant of ZO-2 in which two putative NLSs
[21,29,38] were eliminated (ZO-2-NLS). A truncated version
of ZO-2 that has only the first PDZ domain (ZO-2-N) was also
Figure 2 First PDZ domains of ZO proteins are necessary to bind to YAP2
(A) The ZO-2 first PDZ domain binds to YAP2. Three PDZ domains of mouse ZO-2 were
individually fused to GST and purified with glutathione–Sepharose 4B followed by the incubation
with purified Flag–YAP2-WT. Bound proteins were separated by SDS/PAGE followed by
immunoblotting (IB) or Coomassie Blue staining. Molecular masses (MW) are indicated in kDa
on the left-hand side. (B) K d for GST–PDZ domain 1 of ZO-1 and ZO-2 with human YAP peptide
KLDKESFLTWL. Purified GST fusion proteins were incubated with the synthetic YAP peptides to
determine the K d for the interaction. Microcalorimetric titration measurements were performed
in a Microcal Omega isothermal titration calorimeter (Microcal). All solutions were degassed
under vacuum prior to use. In a typical experiment, 1.33 ml of 15 μM PDZ1-ZO-2 in 20 mM
Hepes, pH 7.5, and 150 mM NaCl was titrated by 20 injections (15 μl) of 150 μM YAP peptide.
During titration, the injection syringe was rotated at 250 rev./min. The time between injections
was 5 min. In a blank experiment, heat evolved from dilution was measured by injecting the
peptide solution into the sample cell filled with buffer only. This heat of dilution was subtracted
from the peptide-binding data for the PDZ domain 1. Data were integrated and fitted to an
appropriate binding model using the Origin software supplied by Microcal.
constructed. Binding assays were conducted with these mutants.
ZO-2-WT could co-precipitate YAP2 effectively (Figure 3B). This
binding between ZO-2 and YAP2 was weakened significantly
when the first PDZ domain of ZO-2 was impaired by the four
point mutations (Figure 3B). The binding of ZO-2-N to YAP2 was
as strong as ZO-2-WT, and this binding signal was stronger than
those of the ZO-2-PDZm, -N or -NLS mutants, suggesting
again that the first PDZ domain of ZO-2 associates with YAP2.
On the basis of the map of PDZ domain-binding specificities
[35] we hypothesized that the complex between YAP2 and ZO-2
is mediated mainly, if not exclusively, by the first PDZ domain.
To test this hypothesis, we used a C mutant of YAP2 lacking
the five C-terminal residues [14], which constitute the PDZ-
binding motif (Figure 3C). Flag-tagged YAP2-WT, YAP2-C
and control vector were transfected into HEK-293 cells followed
by immunoprecipitation and immunoblotting. YAP2-WT bound
strongly to endogenous ZO-2, whereas binding between YAP2-
C and the ZO-2 protein was barely detectable, suggesting that
the PDZ-binding motif in YAP2 is necessary to form the complex
with ZO-2 (Figure 3D). Taken together, our results indicate
c© The Authors Journal compilation c© 2010 Biochemical Society
466 T. Oka and others
Figure 3 Binding between ZO-2 and YAP2
(A) Schematic structure of ZO-2 protein and the ZO-2 mutants . ZO-2 has three PDZ domains, one SH3 domain and one GUK-like (GK) domain. It also contains two putative NLSs (at residues 106–122
and 271–287) and two NESs (at residues 377–386 and 744–754). Point mutations (K38E, F44H, I46E and V48E) were introduced into the first PDZ domain of ZO-2 (ZO-2-PDZm). ZO-2-NLS lacks
both NLSs, whereas ZO-2-N has both NLSs, but lacks both NESs and all the downstream domains. (B) The first PDZ domain of ZO-2 associates with YAP2. Flag-tagged ZO-2-WT, -PDZm, -N,
-NLS and -N were individually transfected with YAP2-WT into HEK-293 cells. Cell lysates were immunoprecipitated (IP) with either control IgG (left-most lane) or anti-YAP antibody, resolved on
SDS gels and immunoblotted (IB) with anti-Flag or anti-YAP antibodies. Molecular masses (MW) are indicated in kDa on the left-hand side. (C) Schematic structure of YAP2 protein and its -C
mutant. YAP2 has two WW domains in its central region and a PDZ-binding motif (PDZ bm) at its C-terminal end. The last five residues (FLTWL) are truncated in the C mutant. TAD, transcription
activation domain. Ser127 (S127) is a phosphorylation site for Lats1 and Akt kinases. (D) The PDZ-binding motif of YAP2 is indispensable for the binding to ZO-2. Flag-tagged cDNAs were transfected
into HEK-293 cells. Cell lysates were immunoprecipitated with anti–Flag antibody, resolved on SDS gels and immunoblotted with anti-ZO-2 or anti-YAP antibodies. Molecular masses are indicated
in kDa on the left-hand side.
that binding between YAP2 and ZO-2 is mediated mainly by
the PDZ-binding motif of YAP2 and the first PDZ domain of
ZO-2.
YAP2 localization is regulated by ZO-2
We showed that the endogenous YAP2 and ZO-2 proteins co-
localize in the nucleus of several cell lines (Figure 1), and both
ZO-2-WT and ZO-2-NLS bound to YAP2, although ZO-2-
WT bound to YAP2 more tightly than ZO-2-NLS (Figure 3B).
To test whether ZO-2-WT and ZO-2-NLS have any influence
on YAP2 localization in MDCK cells, we established MDCK
cells stably expressing ZO-2-WT, ZO-2-NLS or control vector.
ZO-2-WT was distributed in both the cytosol and nucleus, but
the stronger signal was detected in the nuclear fraction. On the
other hand, ZO-2-NLS was detected only in the cytosol fraction
(Figure 4A, top panel). Interestingly, distribution of endogenous
YAP in the nucleus consistently increased when ZO-2-WT was ex-
pressed and it significantly decreased when ZO-2-NLS was
present (Figure 4A, middle panel, lanes 2, 4 and 6). Similar
results were obtained in HEK-293 cells (Supplementary Figure S4
at http://www.BiochemJ.org/bj/432/bj4320461add.htm). These
results support our assumption that ZO-2 regulates the distribution
of YAP in cells. To confirm this assumption further, GFP
(green fluorescent protein)–ZO-2-WT or GFP–ZO-2-NLS were
individually co-transfected with YAP2 tagged with the red
fluorescent protein DsRed into MDCK cells and their localizations
were observed (Figures 4B and 4C). As we had expected, ZO-2-
NLS was generally excluded from the nucleus, whereas
ZO-2-WT was predominantly nuclear in MDCK cells. GFP–ZO-
2-WT co-localized with DsRed–YAP2-WT in the nucleus as well
as in the cytosol (Figure 4B). It was reassuring to see the same
locale for both GFP-tagged ZO-2 and YAP2 as that observed for
the endogenous proteins (Figure 1). The percentage of cells in
which DsRed–YAP2-WT was observed in the nucleus was more
than 75% when GFP–ZO-2-WT was present (Figure 4C). The
percentage of cells in which DsRed–YAP2-WT was observed in
the nucleus was significantly decreased to 11.2% when GFP–
ZO-2-NLS was present (Figure 4C). These results suggest
that ZO-2 can regulate the subcellular localization of YAP2.
To make sure that by generating the ZO-2-NLS deletion
mutant we did not affect the neighbouring PDZ domain, two
binding assays were conducted. Since ZO-2 forms homodimers
as well as heterodimers with ZO-1 via the second PDZ domain
[19,40–42], we verified that both GFP–ZO-2-WT and GFP–
ZO-2-NLS were precipitated by Flag–ZO-2-WT (Figure 4D).
These results suggest that our ZO-2-NLS construct was
still capable of binding to ZO-2. Next, the ability to bind
to YAP2 was tested to rule out the possibility that ZO-2-
NLS fails to bind YAP2 because its first PDZ domain is
not intact. The ZO-2 first PDZ domain is responsible for the
association with YAP2 (Figure 2A) and the domain consists
of 85 amino acids; in the ZO-2-NLS construct the PDZ1
domain lacks 13 amino acids at the C-terminus (see the orange
brackets in Supplementary Figure S3A). Although notably
weaker than with the WT-1stPDZ domain, GST-tagged
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Figure 4 Co-localization of YAP2 and ZO-2
(A) YAP2 accumulates in the nucleus in the presence of ZO-2-WT. Cytosol and nuclear fractions of MDCK cells stably expressing Flag–ZO-2-WT, Flag–ZO-2-NLS or control vector were separated
by using the CelLyticTM NuCLEARTM extraction kit, followed by immunoblotting (IB) with indicated antibodies. Molecular masses (MW) are indicated in kDa on the left. (B) Effects of ZO-2 on the
localization of YAP2. DsRed–YAP2-WT was co-transfected with GFP–ZO-2-WT (upper panels) or GFP–ZO-2-NLS (lower panels) in MDCK cells. The localization of each protein was observed.
The nucleus was stained with DAPI (4′,6-diamidino-2-phenylindole). Scale bar, 20 μm. (C) Graphic representation of results shown in (B). The ratios of nuclear localization of DsRed–YAP2-WT
in the presence of GFP–ZO-2-WT or GFP–ZO-2-NLS are indicated. If the red or green signals overlapped with blue signal of DAPI, the protein was defined as ‘localized in the nucleus’. Cells
expressing both GFP and DsRed constructs were counted, and cells expressing only one of them were eliminated from this evaluation. The experiment was repeated three times independently
and approx. 100 cells were observed in each case. (D) ZO-2-NLS does not lose the ability to form a homodimer. The indicated plasmids were co-transfected into HEK-293 cells. Cell lysates
were immunoprecipitated (IP) with anti-Flag antibodies, resolved via SDS/PAGE, and immunoblotted (IB) with anti-GFP antibody (top panel). The middle and bottom panels show the expression of
transfected proteins. Molecular masses (MW) are indicated in kDa on the left. (E) ZO-2-NLS does not lose the ability to bind to YAP2. The indicated portions of human ZO-2 were individually
fused to GST. GST–1stPDZ-WT contains residues 1–303 of human ZO-2; GST–1stPDZ-NLS contains residues 1–104 and 292–303, and GST–3rdPDZ contains residues 501–600 amino acids.
GST-tagged proteins were purified with glutathione–Sepharose 4B followed by the incubation with purified Flag–YAP2 by using anti-Flag M2 affinity gel (Sigma–Aldrich) and 3 × Flag peptide.
Bound proteins were separated by SDS/PAGE followed by immunoblotting or Coomassie Blue staining. Molecular masses are indicated in kDa on the left-hand side.
ZO-2–1stPDZ-NLS was able to bind to YAP2 in vitro (Figure 4E
and also see Figure 3B).
To confirm further that GFP–ZO-2 functions with YAP2 in the
nucleus, we used the YAP2–RUNX2 (runt-related transcription
factor 2) transactivation assay of the osteocalcin gene, which
was originally reported as the functional ‘read-out’ of YAP
[6]. Increasing amounts of GFP–ZO-2 had an inhibitory effect
on the transactivation function of YAP2–RUNX2 for the
osteocalcin gene luciferase reporter (Supplementary Figure S5
at http://www.BiochemJ.org/bj/432/bj4320461add.htm).
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Figure 5 Removal of ZO-2 weakens the pro-apoptotic function of YAP2
(A) The indicated RNAi oligonucleotides were transfected into HEK-293 cells and YAP2-WT was induced by tetracycline. The cells were cultured in DMEM containing 1 % (v/v) FBS for 96 h. After the
removal of detached cells, attached cells were trypsinized and their numbers were counted. The relative changes in cell numbers (number of cells in which YAP2-WT was induced for 96 h/number
of cells in which YAP2 WT was not induced during 96-h culture) is presented. The ratio of number of YAP2-WT induced cells to number of non-induced cells in each case is shown. Lower panel:
expression of YAP2, ZO-2, ZO-1, GAPDH and PARP were monitored. Molecular masses (MW) are indicated in kDa on the left-hand side. (B) Repression of ZO-2 in HEK-293 cells after RNAi treatment
was confirmed by immunostaining. Endogenous ZO-2 was immunostained and observed by a microscope. Scale bar, 20 μm. (C) The amount of endogenous YAP in the nucleus of HEK-293
cells was decreased when ZO-2 was down-regulated. Cytosol and nuclear fractions of HEK-293 cells were separated by using the CelLyticTM NuCLEARTM extraction kit, followed by immunoblotting
(IB) with indicated antibodies. Molecular masses are indicated in kDa on the left-hand side.
Decrease in endogenous ZO-2 affects the ability of YAP2 to
promote cell detachment
We previously reported that YAP2 promotes cell detachment and
apoptosis in HEK-293 cells [13], and that this function was
impaired when the PDZ-binding motif of YAP2 was deleted
[14]. Since we detected the binding between the PDZ-binding
motif of YAP2 and the first PDZ domain of ZO-2 (Figure 3),
and YAP2 accumulated in the nucleus when ZO-2 was co-
transfected (Figure 4), we hypothesized that ZO-2 regulated the
function of YAP2 in terms of cell detachment. To investigate
this assumption, we down-regulated the level of ZO-2 by RNAi
in HEK-293 cells and monitored changes in YAP2-induced cell
detachment. The expression of YAP2-WT was induced in HEK-
293 cells followed by transfection of either ZO-2-specific RNAi
oligonucleotides or control RNAi oligonucleotides. The efficiency
of this RNAi oligonucleotide was confirmed by immunoblotting
and immunostaining (Figures 5A and 5B), and it was able to
reduce the amount of ZO-2 by more than 99%.
After 96 h of culture in DMEM containing 1% (v/v) serum,
the attached cells were counted. When the control RNAi was
transfected, the ratio of attached cells with induced YAP2-
WT to attached cells without induced YAP2-WT was 0.495
(Figure 5A). However, when ZO-2 RNAi was transfected, the ratio
was increased to 0.650 (Figure 5A). The amount of the cleaved
PARP fragment was decreased when endogenous ZO-2 was down-
regulated (Figure 5A, bottom panel, lanes 2 and 4), suggesting that
apoptosis was repressed. In addition, the amount of YAP in the
nucleus of HEK-293 cells was decreased by 37.2% when ZO-2
was removed (Figure 5C). These results indicate that the ability
of YAP2 to localize in the nucleus and promote cell detachment
and apoptosis in HEK-293 cells was partially impaired when the
level of ZO-2 protein was diminished.
We conducted a comparable assay with MDCK cells. However,
unlike HEK-293 cells, the suppression of ZO-2 in MDCK cells
was never complete in our hands, but only partial, which might
be a reason why ZO-2 RNAi treatment had no influence on
YAP localization in MDCK cells (Supplementary Figure S6 at
http://www.BiochemJ.org/bj/432/bj4320461add.htm).
ZO-2 protein expression enhances YAP2 ability to promote cell
detachment
When endogenous ZO-2 was removed, the ability of YAP2
to promote cell detachment was decreased (Figure 5A). This
result prompted us to test whether the overexpression of ZO-
2-WT (as well as of several ZO-2 mutants) had any effect
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Figure 6 ZO-2 inhibits cell proliferation
(A) ZO-2 enhances pro-apoptotic function of YAP2. HEK-293 cells were transfected with the
indicated plasmids prior to distribution into new plates. The cells were maintained in DMEM
with 1 % (v/v) FBS for 96 h and cell numbers were counted. The growth rate (number of cells
after 96-h culture/number of cells when they were originally plated on the tissue culture dish) is
presented. Protein expression was monitored by immunoblotting (IB) with indicated antibodies.
Molecular masses (MW) are indicated in kDa on the left of the blot. (B) YAP2 induces cell
proliferation in MDCK cells and ZO-2 prevents it. MDCK cells stably expressing the indicated
plasmids were maintained in DMEM with 0.5 % FBS for 96 h. Growth rate and protein expression
were analysed as described in (A).
on the function of YAP2. YAP2 was transfected with several
ZO-2 constructs into HEK-293 cells. At 24 h after trans-
fection, cells were trypsinized and plated at the same density
(25000 cells per plate). After 4 days of culture the number of cells
was counted (Figure 6A). The number of cells transfected with
vector alone increased 16.4-fold. This number of cells in which
YAP2 and the vector were transfected increased to a lesser level
than control, namely 11.6-fold, in agreement with our previous
findings [13,14]. Interestingly, the number of cells in which ZO-2
was co-transfected with YAP2 increased by an even lower level
(9.4-fold). ZO-2-N, a mutant localized in the nucleus, showed a
slightly stronger inhibitory effect (8.8-fold) than ZO-2-WT. Other
mutants (ZO-2-PDZm, -N and -NLS) had minor effects on
YAP2 function to reduce cell proliferation. This might be due
to their weak association with YAP2 (Figure 3). In contrast with
ZO-2, ZO-1-WT did not enhance the ability of YAP2 to promote
cell detachment. PARP cleavage was clearly detectable, especially
when ZO-2-WT or ZO-2-N was overexpressed.
To determine the effects of YAP2 and ZO-2 in other cells,
MDCK and MCF10A cells stably expressing YAP2 and ZO-2
were established. In contrast with HEK-293 cells, YAP2 promotes
cell proliferation in MDCK cells. This effect was abrogated when
ZO-2-WT was co-expressed (Figure 6B). This result is consistent
with previous findings that suggested that ZO-2 in some settings
could act as a tumour suppressor gene [43,44]. ZO-2 mutants
slightly diminished the pro-proliferate effects of YAP2, but these
results were not statistically significant (P > 0.05). For unknown
reasons, the expression of ZO-2-N was consistently weaker than
that of other ZO-2 constructs in these MDCK cells (results not
shown). In MCF10A cells, it was shown that YAP2 induced
EMT (epithelial-to-mesenchymal transition) [45]. Therefore we
decided to see whether ZO-2 had any effect on EMT in MCF10A
cells. In positive and negative control experiments, we reproduced
EMT in MCF10A cells, but the overexpression of ZO-2 had little
or no influence on EMT (results not shown).
Our results suggest that ZO-2 co-operates with YAP2 to
promote cell detachment and apoptosis in HEK-293 cells.
However, in MDCK cells, YAP2 promotes cell proliferation
whereas ZO-2 prevents it. Even though YAP2 accumulates in
the nucleus in the presence of ZO-2, the anti-proliferative effects
of ZO-2 are more dominant than pro-proliferate effects of YAP2
in MDCK cells. Identification of signalling partners downstream
of the YAP2–ZO-2 complex in both cell types will help explain
the functional duality of YAP, which can act either as an oncogene
or a pro-apoptotic factor.
DISCUSSION
The Hippo signalling pathway was delineated as a string of
signalling complexes that involve several tumour suppressors, and
at least two effectors: YAP and TAZ (transcriptional co-activator
with PDZ-binding motif) [also known as WWTR1 (WW-domain-
containing transcription regulator 1)], which display oncogene-
like activity [46,47]. When not affected by genetic lesions, the
components of this pathway control the intrinsic size of organs
by regulating the balance between proliferation and cell death.
Therefore a detailed understanding of the molecular mechanisms
that govern this pathway should help us better understand normal
growth and its abnormal forms, including cancer.
In the present study, we elucidated a new aspect of the
mammalian Hippo pathway, namely the signalling by a YAP2–
ZO-2 complex that is mediated by the PDZ domain of ZO-2. We
showed that the tight junction protein ZO-2 uses its first PDZ
domain to form a complex with YAP2. We also showed that
endogenous ZO-2 and YAP2 co-localize in the nucleus, and
that ZO-2 regulates nuclear localization and the pro-apoptotic
function of YAP2 in HEK-293 cells, and inhibits YAP2-induced
proliferation in MDCK cells. Since the Hippo pathway is activated
by cell-to-cell contacts [33], the identification of a member of
the ZO family of tight junction proteins as a partner of YAP
signalling adds further to the quickly expanding characterization
of the Hippo signalling network [47].
The following aspects of the present study deserve further
comment: (i) the role of ZO-2 among other ZO family
members as the ‘preferred’ partner of YAP2; (ii) the cell-
density-dependent localization of ZO-2 and YAP2 in cells;
(iii) the functional implication of the absence of the PDZ-
domain-binding region in the Drosophila YAP homologue Yki;
(iv) targeting YAP complexes with PDZ-domain-containing
c© The Authors Journal compilation c© 2010 Biochemical Society
470 T. Oka and others
proteins for cancer therapy; and (v) the role of YAP paralogue
TAZ/WWTR1 in assembling functional complexes with ZO
proteins.
We focused our study on ZO-2 as the partner of YAP2 because,
unlike ZO-1, ZO-2 co-localized with YAP2 in the nuclei of kidney
epithelial cells. In addition, co-immunoprecipiations showed a
robust complex between ZO-2 and YAP2 in several cell lines. In
contrast with ZO-1 and ZO-2, ZO-3 has not been reported in the
nucleus, where YAP2 functions as a transcriptional co-activator.
We anticipate that all three ZO proteins have a propensity to
form complexes with YAP2 via their first PDZ domains. Such
complexes could function in specific locales, in specific cells and
under various physiological conditions. For example, ZO-2 is
generally not expressed in non-epithelial cells, whereas ZO-1
is expressed and therefore it could ‘replace’ the ZO-2 function.
It has been shown that at low-cell-density YAP is
unphosphorylated and nuclear. However, when cells reach the
confluent state, YAP is phosphorylated and mainly cytoplasmic
[33]. Interestingly, the subcellular distribution of ZO-1 and ZO-2
proteins is similar to YAP. In epithelial cells cultured in sparse
conditions, ZO-1 and ZO-2 are nuclear. However, in a confluent
state, both these ZO proteins accumulate in tight junctions [26,27].
However, we do observe that in some cell lines, including MDCK
cells, a certain amount of YAP and ZO-2 stay concentrated in
the nuclei, even after the cells were kept in a confluent state
for extended periods of time. Nuclear phospholipids may be a
contributing factor in this observation. PtdIns(4,5)P2 is known
to reside in nuclear speckles of MDCK cells and a recent study
has shown that ZO-2 interacts with PtdIns(4,5)P2 via its second
PDZ domain [48]. Moreover, in that study ZO-2 was shown to
co-localize with nuclear PtdIns(4,5)P2. The possibility of ZO-2
forming a tripartite complex with YAP and PtdIns(4,5)P2 and the
regulatory role of PtdIns(4,5)P2 on the stability or function of
the nuclear YAP–ZO-2 complex remains the subject of further
study. Apparently, cells that harbour a mutation in Merlin, a gene
that encodes one of the cytoplasmic, and possibly also nuclear
component, [49] of the Hippo pathway, have YAP localized in the
nucleus even in high-density cultures [50]. We assessed whether
Merlin was mutated in our stock of MDCK cells, by amplifying
its cDNA and performing sequence analysis and the analysed
sequence of Merlin was identical with that of the WT dog Merlin
cDNA (C. Gaffney, T. Oka and M. Sudol, unpublished work).
It is possible that a mutation in other upstream components of
the Hippo pathway could be responsible for the enhanced and
cell-density-independent nuclear localization of YAP in MDCK
cells.
In the case of the Drosophila YAP homologue Yki, the
C-terminal sequence does not contain a known PDZ-binding
sequence and there is no obvious internal PDZ ligand motif
either [14]. Therefore the signalling of the mammalian YAP
in the Hippo pathway differs in that particular aspect from the
signalling by Yki in the fly. Moreover, the fly seems to be
an exception, as the PDZ-binding motif is well-conserved in
YAP orthologues throughout the animal kingdom. This is true
even in simple Hydra, whose divergence is estimated to have
occurred approx. 1 billion years ago (Supplementary Figure S7
at http://www.BiochemJ.org/bj/432/bj4320461add.htm) [14]. We
suggest that Drosophila Yki must interact with other partner(s)
that act similarly to mammalian ZO-2 protein, regulating the
nuclear transport of Yki and sensing cell-to-cell contacts.
The loss of main components of the Hippo pathway leads to
uncontrolled cell growth, which confirms that this is a tumour
suppressor pathway. YAP, as the effector of the pathway, has been
proposed to act as both an oncogene [51] and tumour suppressor
[52]. The study of YAP expression in common solid tumours
revealed relative changes in the subcellular localization of YAP in
cancer cells compared with the normal controls [53]. Increases in
both cytoplasmic and nuclear localization of YAP protein was
generally observed in these tumours. Since YAP is a nuclear
effector of the Hippo pathway [7,13], controlling its translocation
to the nucleus, by interfering with the PDZ-domain-mediated
complex(es) through small molecular inhibitors, one should be
able to control the growth of cancer cells. This approach could
be feasible since the -TWL sequence is present in the C-termini
of only three human proteins, and the C-terminus of YAP was not
found to bind to other PDZ domains. Apart from YAP, and its
close paralogue TAZ, the -TWL end is also present in MRPL43
(mitochondrial ribosomal protein L43), suggesting that peptides
or mimetics of this sequence could be specific as drugs, with
possible minor side effects, as such drugs would not significantly
affect signalling by other PDZ domain complexes.
Two comments are appropriate here. Because regulatory
interactions are mostly co-operative, and regulatory decisions
in signalling are generally made by large multi-component
complexes and not by single proteins, or simple pair of proteins
[54], we have to consider that there could be other PDZ domain-
containing proteins, outside of the ZO family, which could also
interact with YAP2 and contribute to the global regulation of YAP2
nuclear transport. Such regulations are detectable by signalling
studies using sensitive ‘read-outs’, as shown by our analyses, but
could not always be easily delineated by genetic studies because
of the inherent redundancy.
In a separate study, we most recently documented that the YAP
paralogue TAZ (WWTR1) also interacts with ZO-2 via the PDZ
domain, co-localizes in the nucleus in various cells and affects
transcription of a TAZ-regulated gene [55].
Our work implicates the PDZ domain and PDZ domain-
containing protein ZO-2 in the mechanism of nuclear
translocation of YAP protein, one of the main effectors of the
Hippo tumour suppressor pathway.
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Figure S1 PDZ domains and their host proteins that interact with human
YAP
Five PDZ domains were predicted and tested with the human YAP sequence. The middle column
displays the sequence logo derived from phage peptides [1]. The right-hand column shows the
YAP C-terminus. Amino acids that clearly match the logo are highlighted in red.
1 To whom correspondence should be addressed (email msudol1@geisinger.edu).
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Figure S2 Molecular structures of PDZ-domain-containing proteins that also have NLSs
NLSs were predicted using the PredictNLS software [2]. Non-canonical NLS was also predicted [3]. Modular structure of proteins was taken from SMART [4]. The green rectangle indicates the
localization of NLS within a given protein and the exact position of the first amino acid of the NLS and its sequence are shown in the two right-hand rows. Accession numbers refer to PubMed
Gene IDs. ANK, ankyrin; CH, calponin homology; DAX, domain present in Dishevelled and axin; DEP, domain present in Dishevelled, Egl-10 and pleckstrin; Fha, forkhead-associated; GuKc, GUK;
L27, ribosomal L27; LIM, zinc-binding domain present in Lin-11, Isl-1 and Mec-3; PH, pleckstrin homology; PTB, phosopho-tyrosine binding; RA, RAS-association; RGS, RGS-box; RhoGAP, Rho
GTPase-activating protein; SAM, sterile alpha motif; TCK-S, serine/threonine kinase; TK, tyrosine kinase.
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Figure S3 Sequence and structure of ZO proteins
(A) The first PDZ domains of ZO-1 and ZO-2 are highly similar in sequence and structure. The binding site is highlighted in green and the two non-conserved amino acids in the binding site are
displayed in blue (I48V and F42R). These two changes in the binding site are not expected to alter the specificity because position 42 is on the periphery of the binding site and the change at
position 48 involves two chemically similar residue types. The binding site was defined as in [1] keeping only amino acids with at least one atom at a distance smaller than 4 A˚ from the peptide.
(B) Three-dimensional structure of ZO-1 with a bound peptide (WRRTTYL) [5] (PDB code 2H2B). The same colour code as in (A) is used to highlight the binding site and the amino acids that are
not conserved between ZO-1 and ZO-2. (C) The ZO-2-PDZm mutant disrupts important binding site positions. The four point mutations of ZO-2-PDZm are displayed in purple.
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Figure S4 YAP2 accumulates in the nucleus in the presence of ZO-2-WT in
HEK-293 cells
Expression of ZO-2 was induced by tetracycline in HEK-293 cells, and cytosol or nuclear fractions
were separated by using the CelLyticTM NuCLEARTM extraction kit (Sigma–Aldrich), followed
by immunoblotting (IB) with indicated antibodies. Molecular masses (MW) are indicated in kDa
on the left.
Figure S5 Inhibition of YAP induced transactivation of RUNX2-driven gene
expression by ZO-2
HEK-293 cells were transfected with 1 μg of the firefly luciferase reporter construct
(p6OSE2-Luc), 50 ng of β-galactosidase, 500 ng of the GFP–YAP construct and increasing
concentrations of GFP–ZO-2 DNA (100, 250, 500 and 1000 ng). Total DNA was kept constant
using an empty pEGFP vector. At 24 h after transfection, cells were resuspended and seeded in
a black 96-well plate (Costar). After another 24 h, luciferase activity from triplicate samples was
determined. The cells were lysed in lysis buffer [25 mM Tris/HCl, pH 7.8, 2 mM EDTA, 2 mM DTT
(dithiothreitol) 10 % (v/v) glycerol and 1 % (v/v) Triton X-100] for 15 min at room temperature
and 35 μl of luciferase substrate buffer [20 mM tricine, 1.07 mM (MgCO3)4Mg(OH)2·5H2O,
2.67 mM MgSO4·7H2O, 0.1 mM EDTA, 33.3 mM DTT, 270 μM coenzyme A, 470 μM luciferin
and 530 μM ATP] was added per 50 μl of lysate. Light emission was measured for 5 s in
a TopCount chemiluminescence counter (Packard). Luciferase activity, expressed in arbitrary
light units, was corrected for protein concentration by normalization to β-galactosidase. Each
experimental point was measured in triplicate and the experiment was repeated three times.
Results are expressed as means +− S.E.M.
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Figure S6 Knockdown of ZO-2 has no influence on the localization of YAP in MDCK cells
(A) Immunostaining of ZO-2 (green) and YAP (red) in control MDCK and MDCK cells treated with siRNA targeting ZO-2. Scale bar, 20 μm. (B) Immunoblot (IB) showing partial knockdown of ZO-2
in MDCK cells.
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Figure S7 Conservation of YAP and ZO-2
(A) The YAP C-terminus is well conserved in many species. Amino acids highlighted in blue are not conserved compared with human YAP. (B) The ZO-2 domain architecture is also conserved
in most orthologues. GK, GUK. In sea anemone and Hydra, only one ZO protein is present. Note that two potential NLSs (shown in orange) are present in human and chimpanzee ZO-2 proteins
[2,3]. One of the NLSs is conserved from humans to frog. (C) Multiple sequence alignment of the first PDZ (PDZ1) domains of ZO-2 orthologues. The binding site is shown in green and it is highly
conserved for all species in which the YAP C-terminus is conserved. Blue amino acids highlight non-conserved positions compared with the human PDZ1 domain from ZO-2.
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